Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2025)

Historic Receivables - Accured for SAB Biotherapeutics (SABS) over the last 2 years, with Q3 2025 value amounting to $560000.0.

  • SAB Biotherapeutics' Receivables - Accured rose 47704.0% to $560000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $560000.0, marking a year-over-year increase of 47704.0%. This contributed to the annual value of $55000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that SAB Biotherapeutics reported Receivables - Accured of $560000.0 as of Q3 2025, which was up 47704.0% from $21386.0 recorded in Q1 2025.
  • SAB Biotherapeutics' Receivables - Accured's 5-year high stood at $560000.0 during Q3 2025, with a 5-year trough of $21386.0 in Q1 2025.